Carbon ion radiation therapy for prostate cancer: Results of a prospective phase II study

Radiotherapy and Oncology

Volumn 81, Issue 1, 2006, Pages 57-64

  Ishikawa, Hitoshi ^a   Tsuji, Hiroshi ^a   Kamada, Tadashi ^a   Yanagi, Takeshi ^a   Mizoe, Jun Etsu ^a   Kanai, Tatsuaki ^a   Morita, Shinroku ^a   Wakatsuki, Masaru ^a   Shimazaki, Jun ^a   Tsujii, Hirohiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Carbon ion therapy; Hypofractionated radiotherapy; Phase II study; Prostate cancer; Radiation therapy

Indexed keywords

CARBON; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CASTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; ION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM DISEASE; UROGENITAL TRACT DISEASE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CARBON RADIOISOTOPES; DOSE FRACTIONATION; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIATION INJURIES; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 33749437063     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.08.015     Document Type: Article

References (36)

1. Akakura K., Tsujii H., Morita S., et al. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58 (2004) 252-258
2. Ando K., Koike S., Nojima K., et al. Mouse skin reactions following fractionated irradiation with carbon ions. Int J Radiat Biol 74 (1998) 129-138
3. Bentzen S.M., and Ritter M.A. The alpha/beta ratio for prostate cancer: what is it, really?. Radiother Oncol 76 (2005) 1-3
4. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
5. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
6. Christie D., Denham J., Steigler A., et al. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation. Radiother Oncol 77 (2005) 117-125
7. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
8. Esper P., Mo F., Chodak G., et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50 (1997) 920-928
9. Fiorino C., Cozzarini C., Vavassori V., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 (2002) 1-12
10. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 56 (2003) 1093-1104
11. Goldner G., Zimmermann F., Feldmann H., et al. 3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects. Radiother Oncol 78 (2006) 36-40
12. Hara I., Murakami M., Kagawa K., et al. Experience with conformal proton therapy for early prostate cancer. Am J Clin Oncol 27 (2004) 323-327
13. Kanai T., Endo M., Minohara S., et al. Biophysical characteristics of HIMAC clinical irradiation system for heavy-ion radiation therapy. Int J Radiat Oncol Biol Phys 44 (1999) 201-210
14. Kanai T., Furusawa Y., Fukutsu K., et al. Irradiation of mixed beam and design of spread-out Bragg peak for heavy-ion radiotherapy. Radiat Res 147 (1997) 78-85
15. Kaplan E., and Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
16. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 15 (2002) 904-912
17. Lamb D.S., Denham J.W., Mameghan H., et al. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer. Radiother Oncol 68 (2003) 255-267
18. Laramore G.E., Krall J.M., Thomas F.J., et al. Fast neutron radiotherapy for locally advanced prostate cancer. Final report of Radiation Therapy Oncology Group randomized clinical trial. Am J Clin Oncol 16 (1993) 164-167
19. Martinez A.A., Demanes D.J., Galalae R., et al. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 62 (2005) 1322-1331
20. Nichol A., Chung P., Lockwood G., et al. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 76 (2005) 11-17
21. Nikoghosyan A., Schulz-Ertner D., Didinger B., et al. Evaluation of therapeutic potential of heavy ion therapy for patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 89-97
22. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
23. Pickles T., Kim-Sing C., Morris W.J., et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57 (2003) 11-18
24. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
25. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
26. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose-response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 (2002) 1097-1105
27. Roach M., Lu J., Pilepich M.V., et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47 (2000) 617-627
28. Shipley W.U., Lu J.D., Pilepich M.V., et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 54 (2002) 1302-1310
29. Slater J.D., Rossi Jr. C.J., Yonemoto L.T., et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 59 (2004) 348-352
30. Suzuki M., Kase Y., Yamaguchi H., et al. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys 48 (2000) 241-250
31. Tsuji H., Yanagi T., Ishikawa H., et al. Hypofractionated radiotherapy with carbon ion beams prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1153-1160
32. Tsujii H., Mizoe J.E., Kamada T., et al. Overview of clinical experiences on carbon ion radiotherapy at NIRS. Radiother Oncol 73 suppl. (2004) S41-S49
33. Tsujii H., Morita S., Miyamoto T., et al. Preliminary results of phase I/II carbon-ion therapy at the National Institute of Radiological Sciences. J Brachytherapy Int 13 (1997) 41-49
34. Tsunemoto H., Morita S., Satoh S., et al. Present status of fast neutron therapy in Asian countries. Strahlenther Onkol 165 (1989) 330-336
35. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
36. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 294 (2005) 1233-1239